Sarcoidosis and cancer risk: Systematic review and meta-analysis of observational studies systematic review and meta-analysis of observational studies

Chest

Volumn 147, Issue 3, 2015, Pages 778-791

  Bonifazi, Martina ^a   Bravi, Francesca ^b   Gasparini, Stefano ^c   La Vecchia, Carlo ^b   Gabrielli, Armando ^c   Wells, Athol U ^d   Renzoni, Elisabetta A ^d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; HUMAN; KIDNEY CANCER; LIVER CANCER; MALIGNANT NEOPLASTIC DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SARCOIDOSIS; SKIN CANCER; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; COMPLICATION; FEMALE; LUNG NEOPLASMS; LUNG SARCOIDOSIS; MALE; META ANALYSIS; RISK FACTOR;

FEMALE; HUMANS; LUNG NEOPLASMS; MALE; OBSERVATIONAL STUDY AS TOPIC; RISK FACTORS; SARCOIDOSIS, PULMONARY;

EID: 84924913922     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-1475     Document Type: Article

References (53)

1. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573-581.
2. Spagnolo P, du Bois RM. Genetics of sarcoidosis. Clin Dermatol. 2007;25(3):242-249.
3. Spagnolo P, Schwartz DA. Genetic predisposition to sarcoidosis: another brick in the wall. Eur Respir J. 2013;41(4):778-780.
4. Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol. 2007;25(3):326-333.
5. Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K. Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden. Ann Oncol. 2009;20(6):1121-1126.
6. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007;101(12):2534-2540.
7. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
8. Greenland S. Variance estimators for attributable fraction estimates consistent in both large strata and sparse data. Stat Med. 1987;6(6):701-708.
9. Higgins JP, Th ompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
10. Th ornton A, Lee P. Publication bias in meta-analysis:its causes and consequences. J Clin Epidemiol. 2000;53(2):207-216.
11. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
12. Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med. 1999;160(5 pt 1):1668-1672.
13. Boffetta P, Rabkin CS, Gridley G. A cohort study of cancer among sarcoidosis patients. Int J Cancer. 2009;124(11):2697-2700.
14. Seersholm N, Vestbo J, Viskum K. Risk of malignant neoplasms in patients with pulmonary sarcoidosis. Thorax. 1997; 52(10):892-894.
15. Rømer FK, Hommelgaard P, Schou G. Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients. Eur Respir J. 1998;12(4):906-912.
16. Lindqvist EK, Goldin LR, Landgren O, et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood. 2011;118(24):6284-6291.
17. Landgren O, Engels EA, Pfeiff er RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006;98(18):1321-1330.
18. Mellemkjaer L, Pfeiff er RM, Engels EA, et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum. 2008;58(3):657-666.
19. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60.
20. Kristinsson SY, Landgren O, Sjöberg J, Turesson I, Björkholm M, Goldin LR. Autoimmunity and risk for Hodgkin's lymphoma by subtype. Haematologica. 2009;94(10):1468-1469.
21. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216-1220.
22. Anderson LA, Engels EA. Autoimmune conditions and hairy cell leukemia: an exploratory case-control study. J Hematol Oncol. 2010;3(35):35.
23. Hemminki K, Liu X, Ji J, Försti A, Sundquist J, Sundquist K. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. 2012;127(1):180-185.
24. Tanimoto Y, Kataoka M. Sarcoidosis and malignancy [in Japanese]. Jpn J Chest Dis. 2013;72(8):838-845.
25. Alexandrescu DT, Kauff man CL, Ichim TE, Riordan NH, Kabigting F, Dasanu CA. Cutaneous sarcoidosis and malignancy: An association between sarcoidosis with skin manifestations and systemic neoplasia. Dermatol Online J. 2011;17(1):2.
26. Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol. 2008;181(1):746-755.
27. Sahashi K, Ina Y, Takada K, Sato T, Yamamoto M, Morishita M. Significance of interleukin 6 in patients with sarcoidosis. Chest. 1994;106(1):156-160.
28. Alexandrescu DT, Riordan NH, Ichim TE, et al. On the missing link between inflammation and cancer. Dermatol Online J. 2011;17(1):10.
29. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(suppl 1):S79-S84.
30. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444.
31. Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: macrophage migration inhibitory factor (MIF) - the potential missing link. QJM. 2010;103(11):831-836.
32. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45.
33. Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-135.
34. Bonifazi M, Tramacere I, Pomponio G, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford). 2013;52(1):143-154.
35. Wahlström J, Dengjel J, Persson B, et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. 2007;117(11):3576-3582.
36. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 2012;32(4):1119-1136.
37. Javierre BM, Esteller M, Ballestar E. Epigenetic connections between autoimmune disorders and haematological malignancies. Trends Immunol. 2008;29(12): 616-623.
38. Papanikolaou IC, Sharma OP. The relationship between sarcoidosis and lymphoma. Eur Respir J. 2010;36(5):1207-1209.
39. Baughman RP, Teirstein AS, Judson MA, et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 pt 1):1885-1889.
40. Newman LS, Rose CS, Bresnitz EA, et al ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324-1330.
41. Valeyre D, Soler P, Clerici C, et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax. 1988;43(7):516-524.
42. Douglas JG, Middleton WG, Gaddie J, et al. Sarcoidosis: a disorder commoner in non-smokers? Thorax. 1986;41(10):787-791.
43. Harf RA, Ethevenaux C, Gleize J, Perrin-Fayolle M, Guerin JC, Ollagnier C. Reduced prevalence of smokers in sarcoidosis. Results of a case-control study. Ann N Y Acad Sci. 1986;465 :625-631.
44. McGhee JR, Fujihashi K. Inside the mucosal immune system. PLoS Biol. 2012;10(9):e1001397.
45. Paparel P, Devonec M, Perrin P, et al. Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24(2):95-101.
46. Rayson D, Burch PA, Richardson RL. Sarcoidosis and testicular carcinoma. Cancer. 1998;83(2):337-343.
47. Tjan-Heijnen VC, Vlasveld LT, Pernet FP, Pauwels P, De Mulder PH. Coincidence of seminoma and sarcoidosis: a myth or fact? Ann Oncol. 1998;9(3):321-325.
48. Cook MB, Chia VM, Berndt SI, et al. Genetic contributions to the association between adult height and testicular germ cell tumors. Int J Epidemiol. 2011;40(3):731-739.
49. Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014;5(5):197.
50. Beyaert R, Beaugerie L, Van Assche G, et al. Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer. 2013;12(1):98.
51. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68(7):1100-1104.
52. Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41(1):21-28.
53. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19(5):545-561.